Skip to content
Clinical Trials – home
Not yet recruiting

Safety and immune response of investigational mRNA vaccine GSKVX000000078664 versus drug combination in adults with flu and COVID-19

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on two common viral infections, Influenza and COVID-19. Participants will receive an investigational mRNA Seasonal Flu/COVID-19 combination vaccine, which uses a small piece of genetic material (mRNA) to teach the body’s cells to produce a harmless part of the viruses so the immune system can learn to recognize them. For comparison, some participants may receive a standard flu shot, the COVID‑19 vaccine known as tozinameran, or the COVID‑19 vaccine called elasomeran. The vaccine is given as a single injection into the muscle.

The purpose of the study is to assess the safety and immune response of the vaccine. After the injection, blood samples are taken before vaccination and again about a month later to measure the level of protective proteins called antibodies, using a test called HI titers. Participants are asked to record any mild side effects such as soreness at the injection site, fever, or fatigue for the first week, and they are monitored for any health changes for up to six months. This schedule helps researchers understand how well the vaccine works and whether it is well tolerated.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Visit and Randomization

    You attend the first study visit after you have agreed to take part. During this visit, study staff confirm that you meet the eligibility criteria and collect basic health information.

    You are randomly assigned to receive either the investigational mRNA seasonal flu/COVID-19 combination vaccine or a comparator vaccine (either a trivalent influenza vaccine, tozinameran, or elasomeran).

  2. Step 2

    Administration of Study Vaccine

    A single dose of the assigned vaccine is given by an intramuscular injection. The exact amount of the vaccine is not disclosed, but the injection is performed in the upper arm.

    After the injection, you remain under observation for about 30 minutes so that study staff can monitor any immediate reactions.

  3. Step 3

    Day 1 Safety Check and Symptom Diary

    On the same day as the injection, you receive a paper or electronic diary in which you record any pain, redness, swelling at the injection site, and any general symptoms such as fever, headache, or fatigue that occur within the first 7 days.

    A brief health check may be performed to record any early side effects.

  4. Step 4

    Day 8 Follow‑Up Visit

    Approximately one week after vaccination, you attend a follow‑up visit (or a telephone call) where study staff review your symptom diary, ask about any new or worsening side effects, and may take a small blood sample to check basic safety laboratory values.

  5. Step 5

    Day 29 Immunogenicity Assessment

    Four weeks after the injection, you return for a visit during which a blood sample is drawn to measure your immune response. This includes testing for influenza hemagglutination inhibition (HI) titers and serum neutralization titers against the SARS‑CoV‑2 spike protein.

    Study staff also ask about any side effects that have occurred since the previous visit and record any unsolicited adverse events that began within the past 28 days.

  6. Step 6

    Extended Safety Monitoring (Months 2–6)

    During the next five months, you may be contacted periodically (by phone or clinic visit) to report any serious adverse events, medically‑attended adverse events, or events of special interest.

    No additional vaccine doses are given; the focus is on observing how your body continues to respond over time.

  7. Step 7

    Final Study Visit (Month 6)

    At the end of the 6‑month follow‑up period, you attend a final visit where a last blood sample may be taken to complete the immune‑response assessment.

    Study staff review the entire safety record, answer any remaining questions, and close your participation in the study.

Who can join the trial?

7 criteria

  • Be able to follow the study requirements (such as completing an electronic diary and attending follow‑up visits) either on your own or with help from a caregiver.
  • Provide written informed consent (sign a form agreeing to join the study) before any study procedures are done.
  • Be at least 50 years old at the first study visit.
  • Be a healthy person or have a stable medical condition (a chronic disease that has not needed major changes in treatment or a hospital stay for worsening symptoms in the past 3 months).
  • Have a body weight and height that give a BMI (body‑mass‑index, a measure of weight relative to height) between 18 and 33 kg/m², inclusive.
  • If you are of non‑childbearing potential (you cannot become pregnant), you may join the study.
  • If you are of childbearing potential (you can become pregnant), you may join only if you have used reliable birth control (adequate contraception) for at least 30 days before the study, have a negative pregnancy test within 24 hours before the study intervention, and agree to continue using birth control for at least 8 weeks after the study intervention.

Who cannot join the trial?

25 criteria

  • Blood tests that check liver health (including the enzymes ALT, AST, ALP and the substance bilirubin) are higher than the normal range at the screening visit.
  • Having a sudden (acute) or ongoing (chronic) serious illness that affects the lungs, heart, kidneys, or other major organs, as judged by the doctor’s exam or lab tests.
  • Having had an allergic reaction (called hypersensitivity) to any flu or COVID‑19 vaccine in the past.
  • Having had an allergic reaction to any previous mRNA vaccine (a type of vaccine that uses messenger RNA).
  • Any other health condition that the doctor believes could increase the risk of taking part in the study.
  • Any illness that could make the study results unclear or add extra risk for the participant.
  • Using any experimental or non‑registered drug, vaccine, or medical device (called an investigational product) within 30 days before the first study dose or planning to use one during the study.
  • Receiving a flu vaccine within 181 days before the first study dose or planning to receive one within 28 days after the study dose.
  • Receiving a COVID‑19 vaccine that contains the SARS‑CoV‑2 antigen within 91 days before the first study dose or planning to receive one within 28 days after the study dose.
  • Receiving any mRNA‑based vaccine within 29 days before the first study dose or planning to receive one within 28 days after the study dose.
  • Receiving any other vaccine not listed in the study plan within 29 days before the first study dose or planning to receive one within 28 days after the study dose.
  • Having a current or long‑term liver disease or known problems with the liver or bile ducts.
  • Receiving blood products such as immunoglobulins (antibody preparations) or plasma derivatives within 90 days before the first study dose or planning to receive them during the study.
  • Using immune‑modifying medicines for more than 14 days in total, or planning to use long‑acting immune‑modifying treatments, including high‑dose steroids (prednisone ≥ 20 mg per day), drugs that block inflammation proteins (TNF‑inhibitors), lab‑made proteins (monoclonal antibodies), or cancer medicines.
  • Being enrolled in another clinical study that involves an investigational or non‑investigational drug or device at any time during this study.
  • Having a history of heavy alcohol use or drug abuse in the past 5 years that might prevent accurate safety reporting or following study procedures.
  • Being a study staff member or an immediate family or household member of someone who works on the study.
  • Being pregnant or breastfeeding (lactating).
  • Having a confirmed flu infection within the past 180 days or a confirmed COVID‑19 infection within the past 90 days before the first study dose.
  • Having had Guillain‑Barré syndrome (GBS) within 6 weeks after any vaccine.
  • Having a serious underlying illness that the doctor thinks would stop you from completing the study, such as a disease expected to limit survival to less than one year.
  • Having a known weakened immune system (immunosuppression) or immune deficiency, except for stable HIV infection that meets specific treatment and lab criteria.
  • Having a past or current suspicion of heart inflammation (myocarditis) or lining inflammation (pericarditis), or other heart conditions that raise the risk of these problems, including cocaine use, heart muscle disease, or rare blood‑vessel or heart disorders.
  • Having any reaction or allergy that could be made worse by any part of the study vaccine.
  • Being allergic to latex.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • GSKVX000000078664 combination vaccine

    is an experimental vaccine being tested for the first time. It contains messenger RNA (mRNA) that tells the body’s cells to make parts of both the seasonal flu virus and the COVID‑19 virus. By showing these pieces to the immune system, the vaccine aims to teach the body to recognize and fight both illnesses if it encounters them later. In the study, the vaccine is given as a liquid that is injected into a muscle.

  • Efluelda

    is a trivalent influenza vaccine that protects against three strains of the flu virus: two types of influenza A (H1N1 and H3N2) and one type of influenza B. The vaccine contains inactivated (killed) virus particles, so it cannot cause flu. It is given as an injection into the muscle to help the immune system develop antibodies that can prevent flu infection during the season.

  • Influsplit

    is another trivalent influenza vaccine designed for the 2026/2027 flu season. Like Efluelda, it includes inactivated virus from two influenza A strains and one influenza B strain. The vaccine is administered by injection into the muscle and works by stimulating the body’s immune response so that it can recognize and fight the flu viruses that are expected to circulate that season.

  • Tozinameran

    is an mRNA COVID‑19 vaccine (the same technology used in some widely known COVID‑19 shots). The vaccine contains mRNA that instructs cells to produce a harmless piece of the SARS‑CoV‑2 spike protein, prompting the immune system to build protection against COVID‑19. It is given as a muscle injection.

  • Elasomeran

    is also an mRNA COVID‑19 vaccine. Similar to Tozinameran, it delivers mRNA that causes the body’s cells to make a small part of the coronavirus spike protein, training the immune system to recognize and fight the real virus. The vaccine is administered by injection into a muscle.

What is already known about the treatment

  • Investigational mRNA Seasonal Flu/COVID‑19 Combination Vaccine

    This vaccine is given as an intramuscular injection in a liquid form. It is still experimental and currently being studied in early‑phase clinical trials, so it is not yet approved for general use. It is designed to protect adults against both seasonal influenza and COVID‑19. The vaccine uses messenger RNA to tell body cells to produce pieces of flu and coronavirus proteins, which then train the immune system to recognize the real viruses. It belongs to the class of mRNA combination vaccines.

  • Efluelda

    Efluelda is administered by intramuscular injection as a suspension. It is an approved, widely used seasonal flu vaccine that protects against influenza A (H1N1 and H3N2) and influenza B viruses. The vaccine contains killed (inactivated) virus particles that safely stimulate the body’s immune response. It is classified as an inactivated influenza vaccine.

  • Tozinameran

    Tozinameran is given as an intramuscular injection in a liquid form. It is an approved COVID‑19 vaccine (Pfizer‑BioNTech) that is used to prevent infection with the SARS‑CoV‑2 virus. The vaccine carries messenger RNA that directs cells to make the virus’s spike protein, prompting the immune system to build protection. It belongs to the class of mRNA vaccines.

  • Elasomeran

    Elasomeran is administered intramuscularly as a liquid injection. It is an approved COVID‑19 vaccine (Moderna) intended to prevent COVID‑19 disease. Like other mRNA vaccines, it delivers genetic instructions for the spike protein of SARS‑CoV‑2, which triggers an immune response. It is classified as an mRNA vaccine.

  • Influsplit

    Influsplit is given by intramuscular injection as a suspension. It is an approved seasonal influenza vaccine for the 2026/2027 flu season, covering influenza A (H1N1 and H3N2) and influenza B strains. The product contains inactivated (killed) virus particles that safely activate the immune system to fight flu viruses. It falls under the category of inactivated influenza vaccines.

Investigated diseases

  • Influenza

    Influenza is an acute respiratory infection caused by influenza viruses that spreads through droplets when an infected person coughs or sneezes. Symptoms usually begin suddenly with fever, chills, cough, sore throat, muscle aches, and fatigue. The virus first multiplies in the upper airways and can then move into the lower respiratory tract. Peak symptoms typically occur 2 to 3 days after onset and then start to improve. Most people recover within about a week, although a lingering cough or tiredness may last longer.

  • COVID-19

    COVID-19 is the disease caused by the SARS‑CoV‑2 virus, transmitted mainly by respiratory droplets and close contact. It often starts with fever, cough, loss of smell or taste, and mild fatigue. The virus initially infects cells in the nose and throat and can spread to the lungs, leading to increased respiratory symptoms. Over several days, symptoms may become more pronounced, with cough and shortness of breath developing as the infection progresses. Recovery usually occurs within a few weeks, although some people may experience lingering mild symptoms.

Trial detailsLast updated 17 Nov 2026
Age18+ yearsPhasePhase ITrial ID2025-524455-31-00Protocol code300768Estimated enrolment1 075 patientsSponsorGlaxoSmithKline Biologicals

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.